ONE SYSTEM IMPACTS
EVERY AREA OF HUMAN HEALTH
Our deep understanding of the endocrine system and patient needs are at the very center of Crinetics’ DNA. Our founders’ roots in endocrinology, our deep bench of leading endocrinologists, and our world-class R&D capabilities have produced a robust pipeline of transformative novel molecules that are purposefully designed to meet the needs of patients with endocrine and endocrine-rooted disease.
Our expertise in endocrinology and GPCRs is transforming endocrine disease treatment from discovery to commercialization.
Our partners
Targeted radiotherapy for multiple solid tumors
SST2 agonist for life span extension in dogs
Paltusotine partnering with SKK in Japan
A closer look at our late-stage drug candidates
Paltusotine
Paltusotine is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome.
Learn MoreAtumelnant
Atumelnant is the first investigational once-daily, oral melanocortin type 2 receptor (MC2R) receptor antagonist that selectively blocks the activity of ACTH at the adrenal gland. Atumelnant is currently in clinical development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome (ADCS).
Learn More
CRN09682 (non-peptide drug conjugate)
CRN09682 is a potentially first-in-class, non-peptide drug conjugate therapy designed to selectively target and deliver monomethyl auristatin E (MMAE) to SST2-expressing tumor cells. It is currently in clinical development in SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. A Phase 1 clinical trial evaluating CNR09682 in NETs is anticipated to begin enrollment in 2025.
Early-stage pipeline progress
Three early-stage programs from these discovery efforts are currently in IND-enabling studies. The candidates with near-term planned INDs include a TSH antagonist for Graves’ hyperthyroidism and Graves’ orbitopathy (thyroid eye disease), an SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD), and a PTH antagonist for hyperparathyroidism.
Transforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.